XOMA Royalty Corporation (XOMA) Covered Calls
Xoma Ltd is a biopharmaceutical company, which is engaged in the discovery, development and manufacture of therapeutic antibodies and other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases.
You can sell covered calls on XOMA Royalty Corporation to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for XOMA (prices last updated Mon 12:55 PM ET):
| XOMA Royalty Corporation (XOMA) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 27.09 | +1.11 | 26.88 | 27.49 | 149K | - | 0.3 |
| Covered Calls For XOMA Royalty Corporation (XOMA) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 25 | 0.50 | 26.99 | -7.4% | -225.1% | |
| Apr 17 | 25 | 1.10 | 26.39 | -5.3% | -48.4% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Extended Business Description
XOMA Corp. discovers and develops innovative antibody-based therapeutics. It combines a portfolio of innovative therapeutic antibodies, both in late-stage clinical development and in preclinical research, with its recently launched commercial operations. The company focuses its antibody research and development on allosteric modulation, which offers opportunities for new classes of therapeutic antibodies to treat a wide range of human diseases. It is developing its lead product gevokizumab (IL-1 beta modulating antibody) with Servier through a global Phase 3 program in non-infectious uveitis and ongoing proof-of-concept studies in other IL-1-mediated diseases. The company's scientific research also produced the XMet program, which consists of three classes of preclinical antibodies, including Selective Insulin Receptor Modulators that could have a major effect on the treatment of diabetes. XOMA was founded by Patrick J. Scannon in 1981 and is headquartered in Berkeley, CA.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | PATH covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | CTMX covered calls | |
| 3. | EEM covered calls | 8. | GLD covered calls | 3. | OWL covered calls | |
| 4. | SPY covered calls | 9. | FXI covered calls | 4. | USO covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | KSS covered calls | |
Want more examples? XOM Covered Calls | XOP Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
